Curia to acquire Integrity Bio

By The Science Advisory Board staff writers

July 13, 2021 -- Curia, formerly known as Albany Molecular Research (AMRI), has inked a definitive agreement to acquire drug formulation and fill-finish provider Integrity Bio.

Integrity Bio's biologic capabilities are complementary with Curia's existing business and will expand on biologic formulation and fill-finish commercial manufacturing capabilities it currently provides at three facilities in Albuquerque, NM; Burlington, MA; and Glasgow, Scotland, according to Curia. In addition, Integrity Bio will add West Coast coverage to Curia's East Coast and European capabilities, Curia said.

Subject to standard and customary closing conditions, the deal is expected to be completed in the third quarter. Terms of the agreements were not disclosed.

AMRI rebrands as Curia
Albany Molecular Research (AMRI) has changed its name to Curia, effective July 12.
Integrity Bio announces new manufacturing line
Integrity Bio announced the validation of its second fill/finish manufacturing line in Thousand Oaks, CA. The plant expansion more than doubles the company's...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter